{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:20:14Z","timestamp":1790396414473,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007772","name":"Agir pour les Maladies Chroniques","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007772","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.phrs.2018.06.014","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T19:15:00Z","timestamp":1529349300000},"page":"311-319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Cysteinyl-leukotriene pathway as a new therapeutic target for the treatment of atherosclerosis related to obstructive sleep apnea syndrome"],"prefix":"10.1016","volume":"134","author":[{"given":"Elodie","family":"Gautier-Veyret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"B\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Bela\u00efdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1128-6529","authenticated-orcid":false,"given":"Renaud","family":"Tamisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"L\u00e9vy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Arnol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Perrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"P\u00e9pin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Stanke-Labesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2018.06.014_bib0005","article-title":"Obstructive sleep apnoea syndrome","volume":"15015","author":"L\u00e9vy","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.phrs.2018.06.014_bib0010","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1378\/chest.128.5.3407","article-title":"The severity of oxygen desaturation is predictive of carotid wall thickening and plaque occurrence","volume":"128","author":"Baguet","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.phrs.2018.06.014_bib0015","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1164\/rccm.200503-340OC","article-title":"Early signs of atherosclerosis in obstructive sleep apnea","volume":"172","author":"Drager","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.phrs.2018.06.014_bib0020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cvr\/cvt247","article-title":"Leukotrienes as a molecular link between obstructive sleep apnoea and atherosclerosis","volume":"101","author":"Stanke-Labesque","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.phrs.2018.06.014_bib0025","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1111\/bph.12665","article-title":"Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR review 7","volume":"171","author":"B\u00e4ck","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2018.06.014_bib0030","doi-asserted-by":"crossref","first-page":"10967","DOI":"10.1074\/jbc.C113.453704","article-title":"Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand","volume":"288","author":"Kanaoka","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2018.06.014_bib0035","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/07853890600982737","article-title":"Leukotriene receptors in atherosclerosis","volume":"38","author":"B\u00e4ck","year":"2006","journal-title":"Ann. Med."},{"key":"10.1016\/j.phrs.2018.06.014_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/2432958","article-title":"Role of the cysteinyl leukotrienes in the pathogenesis and progression of cardiovascular diseases","author":"Colazzo","year":"2017","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.phrs.2018.06.014_bib0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1183\/09031936.00137107","article-title":"Leukotriene B4: early mediator of atherosclerosis in obstructive sleep apnoea?","volume":"32","author":"Lefebvre","year":"2008","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.phrs.2018.06.014_bib0050","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1194\/jlr.P022814","article-title":"Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea","volume":"53","author":"Stanke-Labesque","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.phrs.2018.06.014_bib0055","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1164\/rccm.201012-2039OC","article-title":"Leukotriene B4 receptor-1 mediates intermittent hypoxia-induced atherogenesis","volume":"184","author":"Li","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"364\u2013370","key":"10.1016\/j.phrs.2018.06.014_bib0060","first-page":"370","article-title":"Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia","volume":"124","author":"Stanke-Labesque","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.phrs.2018.06.014_bib0065","first-page":"1","article-title":"The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field","author":"Hoxha","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.06.014_bib0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pharmthera.2017.12.006","article-title":"Which place of pharmacological approaches beyond continuous positive airway pressure to treat vascular disease related to obstructive sleep apnea?","volume":"186","author":"Gautier-Veyret","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2018.06.014_bib0075","doi-asserted-by":"crossref","first-page":"597","DOI":"10.5664\/jcsm.2172","article-title":"Rules for scoring respiratory events in sleep: update of the 2007 AASM manual for the scoring of sleep and associated events. Deliberations of the sleep apnea definitions task force of the American Academy of Sleep Medicine","volume":"8","author":"Berry","year":"2012","journal-title":"J. Clin. Sleep. Med."},{"key":"10.1016\/j.phrs.2018.06.014_bib0080","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1164\/ajrccm.163.2.9808132","article-title":"Classification of sleep-disordered breathing","volume":"163","author":"Hosselet","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.phrs.2018.06.014_bib0085","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2018.06.014_bib0090","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/ilar.50.3.262","article-title":"Cardiovascular consequences of sleep-disordered breathing: contribution of animal models to understanding the human disease","volume":"50","author":"Dematteis","year":"2009","journal-title":"ILAR J."},{"key":"10.1016\/j.phrs.2018.06.014_bib0095","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1183\/09031936.00096512","article-title":"Intermittent hypoxia-activated cyclooxygenase pathway: role in atherosclerosis","volume":"42","author":"Gautier-Veyret","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.phrs.2018.06.014_bib0100","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.RES.0000264498.60702.0d","article-title":"5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation","volume":"100","author":"B\u00e4ck","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2018.06.014_bib0105","doi-asserted-by":"crossref","first-page":"8161","DOI":"10.1073\/pnas.0602414103","article-title":"Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability","volume":"103","author":"Qiu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.06.014_bib0110","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1161\/CIRCULATIONAHA.107.747667","article-title":"Multidrug resistance protein-1 affects oxidative stress, endothelial dysfunction, and atherogenesis via leukotriene C4 export","volume":"117","author":"Mueller","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2018.06.014_bib0115","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1100\/tsw.2010.229","article-title":"Montelukast: more than a cysteinyl leukotriene receptor antagonist?","volume":"10","author":"Tintinger","year":"2010","journal-title":"Sci. World J."},{"key":"10.1016\/j.phrs.2018.06.014_bib0120","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.prostaglandins.2005.10.001","article-title":"Urinary leukotriene E4 excretion is increased in type 1 diabetic patients: a quantification by liquid chromatography-tandem mass spectrometry","volume":"78","author":"Hardy","year":"2005","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.phrs.2018.06.014_bib0125","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1158\/1940-6207.CAPR-09-0005","article-title":"Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway","volume":"2","author":"Duffield-Lillico","year":"2009","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.phrs.2018.06.014_bib0130","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.5665\/SLEEP.1178","article-title":"Urinary leukotriene E4, obesity, and adenotonsillar hypertrophy in Chinese children with sleep disordered breathing","volume":"34","author":"Shen","year":"2011","journal-title":"Sleep"},{"key":"10.1016\/j.phrs.2018.06.014_bib0135","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jacc.2008.05.002","article-title":"Sleep apnea and cardiovascular disease: an American Heart Association\/American College of Cardiology Foundation Scientific statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on","volume":"52","author":"Somers","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2018.06.014_bib0140","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/heartjnl-2014-305816","article-title":"Body fat percentage, body mass index and waist-to-hip ratio as predictors of mortality and cardiovascular disease","volume":"100","author":"Myint","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.phrs.2018.06.014_bib0145","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.06.014_bib0150","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.atherosclerosis.2016.04.013","article-title":"Urinary cysteinyl leukotrienes in one-year follow-up of percutaneous transluminal angioplasty for peripheral arterial occlusive disease","volume":"249","author":"Maga","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2018.06.014_bib0155","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-2362.2010.02261.x","article-title":"Sulfido-peptide leukotrienes in coronary heart disease \u2013 relationship with disease instability and myocardial ischaemia","volume":"40","author":"De Caterina","year":"2010","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.phrs.2018.06.014_bib0160","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/acel.12488","article-title":"Age-associated vascular inflammation promotes monocytosis during atherogenesis","volume":"15","author":"Du","year":"2016","journal-title":"Aging Cell"},{"key":"10.1016\/j.phrs.2018.06.014_bib0165","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12026-015-8703-8","article-title":"Chronic intermittent hypoxia exposure-induced atherosclerosis: a brief review","volume":"63","author":"Song","year":"2015","journal-title":"Immunol. Res."},{"key":"10.1016\/j.phrs.2018.06.014_bib0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041786","article-title":"Cysteinyl leukotriene signaling aggravates myocardial hypoxia in experimental atherosclerotic heart disease","volume":"7","author":"Nobili","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2018.06.014_bib0175","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.4049\/jimmunol.0902594","article-title":"Hypoxia-mediated expression of 5-lipoxygenase-activating protein involves HIF-1alpha and NF-kappaB and microRNAs 135a and 199a-5p","volume":"184","author":"Gonsalves","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2018.06.014_bib0180","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1089\/ars.2007.1691","article-title":"HIF-1-dependent respiratory, cardiovascular, and redox responses to chronic intermittent hypoxia","volume":"9","author":"Semenza","year":"2007","journal-title":"Antioxid. Redox Signalling"},{"key":"10.1016\/j.phrs.2018.06.014_bib0185","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1113\/jphysiol.2008.157669","article-title":"Interdependent roles for hypoxia inducible factor and nuclear factor-\u03baB in hypoxic inflammation","volume":"586","author":"Taylor","year":"2008","journal-title":"J. Physiol."},{"key":"10.1016\/j.phrs.2018.06.014_bib0190","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.atherosclerosis.2008.11.012","article-title":"Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model","volume":"205","author":"Ge","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2018.06.014_bib0195","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10557-009-6211-6","article-title":"Montelukast inhibits matrix metalloproteinases expression in atherosclerotic rabbits","volume":"23","author":"Liu","year":"2009","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.phrs.2018.06.014_bib0200","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.1073\/pnas.1115313109","article-title":"Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice","volume":"109","author":"Yu","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.06.014_bib0205","first-page":"633","article-title":"The effect of montelukast on atherogenesis in apoE\/LDLR-double knockout mice","volume":"59","author":"Jawien","year":"2008","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.phrs.2018.06.014_bib0210","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCIMAGING.110.937169","article-title":"Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome","volume":"3","author":"Tardif","year":"2010","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"10.1016\/j.phrs.2018.06.014_bib0215","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jaci.2011.11.052","article-title":"Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease","volume":"129","author":"Ingelsson","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.phrs.2018.06.014_bib0220","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/thoraxjnl-2012-202178","article-title":"Continuous positive airway pressure improves sleepiness but not calculated vascular risk in patients with minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised controlled trial","volume":"67","author":"Craig","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.phrs.2018.06.014_bib0225","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1136\/thoraxjnl-2012-202807","article-title":"Obstructive sleep apnoea and metabolic syndrome: put CPAP efficacy in a more realistic perspective","volume":"67","author":"P\u00e9pin","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.phrs.2018.06.014_bib0230","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMoa1606599","article-title":"CPAP for prevention of cardiovascular events in obstructive sleep apnea","volume":"375","author":"McEvoy","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.06.014_bib0235","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1164\/rccm.201601-0088OC","article-title":"Effect of positive airway pressure on cardiovascular outcomes in coronary artery disease patients with non-sleepy obstructive sleep apnea: the RICCADSA randomized controlled trial","volume":"194","author":"Peker","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.phrs.2018.06.014_bib0240","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1164\/rccm.200912-1803OC","article-title":"Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea","volume":"182","author":"P\u00e9pin","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.phrs.2018.06.014_bib0245","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1164\/rccm.201505-0998OC","article-title":"Blood pressure response to losartan and continuous positive airway pressure in hypertension and obstructive sleep apnea","volume":"193","author":"Thunstr\u00f6m","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.phrs.2018.06.014_bib0250","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1183\/09031936.00032314","article-title":"The different clinical faces of obstructive sleep apnoea: a cluster analysis","volume":"44","author":"Ye","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.phrs.2018.06.014_bib0255","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.sleep.2014.10.019","article-title":"Nocturia is an independent predictive factor of prevalent hypertension in obstructive sleep apnea patients","volume":"16","author":"Destors","year":"2015","journal-title":"Sleep. Med."},{"key":"10.1016\/j.phrs.2018.06.014_bib0260","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/jsr.12344","article-title":"Phenotypes of comorbidity in OSAS patients: combining categorical principal component analysis with cluster analysis","volume":"25","author":"Vavougios","year":"2015","journal-title":"J. Sleep. Res."},{"key":"10.1016\/j.phrs.2018.06.014_bib0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157318","article-title":"Obstructive sleep apnea: a cluster analysis at time of diagnosis","volume":"11","author":"Bailly","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2018.06.014_bib0270","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jacc.2015.06.1315","article-title":"Precision medicine in patients with resistant hypertension and obstructive sleep apnea: blood pressure response to continuous positive airway pressure treatment","volume":"66","author":"S\u00e1nchez-de-la-Torre","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2018.06.014_bib0275","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jacc.2015.07.014","article-title":"Measuring blood microRNAs to provide personalized advice to sleep apnea patients with resistant hypertension: dreaming the future","volume":"66","author":"McEvoy","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2018.06.014_bib0280","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00408-006-0001-8","article-title":"Relationship between urinary cysteinyl leukotriene E4 levels and clinical response to antileukotriene treatment in patients with asthma","volume":"185","author":"Cai","year":"2007","journal-title":"Lung"},{"issue":"4","key":"10.1016\/j.phrs.2018.06.014_bib0285","first-page":"233","article-title":"Urinary cysteinyl leukotriene E4 level and therapeutic response to montelukast in children with mild obstructive sleep apnea","volume":"35","author":"Sunkonkit","year":"2018","journal-title":"Asian Pac. J. Allergy Immunol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818301749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818301749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:00:10Z","timestamp":1760911210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661818301749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":57,"alternative-id":["S1043661818301749"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2018.06.014","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cysteinyl-leukotriene pathway as a new therapeutic target for the treatment of atherosclerosis related to obstructive sleep apnea syndrome","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2018.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}